MAGE-A4 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene"

MAGE-A4 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene" - MAGE-A4 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene"

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006507

Enrollment

Registered

2011-10-09

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Therapy-resistant esophageal cancer

Interventions

subcutaneous injection of MAGE-A4 peptide, 300microgram mixed with Montanide ISA-51 VG

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient who completed "adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene(UMIN000002395)" 2.adverse events whith grade 1 or 2 during the above study 3.Performance status(ECOG) 0 to 1 4.Having written informed consent

Exclusion criteria

Exclusion criteria: 1.Having following serious complications # Uncontrolled anigina pectoris, myocardial infarction, or heart failure # Uncontrolled diabetes mellitus or hytertention # Uncontrolled infection # X-ray-proven interstitial pneumonia or pulmonary fibrosis # Autoimmune disease # Bleeding tendency; PT less than 50%, APTT more than 60sec, serum fibrinogen less than 100mg/dL, FDP more than 20ug/mL Thrombosis tendency 2.History of serious hypersensitivity 3.Unctrolled pleural effusion, ascites, or pericardial effusion 4.Uncontrolled CNS metastasis 5.Systemic corticostoroid or immuno-suppressive therapy 6. Inappropriate for MAGE-A4 143-151 peptide administration, i.e. allergic to the peptide or adjuvant 7.Mental illness or drug dependency affecting informed consent 8.Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant, or willing male partner, except having cryopreseved sperm 9. Lasting less than four weeks from the previous enrollment to clinical trials 11.Inappropriate for study entry judged by an attending physician

Design outcomes

Primary

Measure	Time frame
safety immune reaction	—

Countries

Japan

Contacts

Public ContactShinichi Kageyama

Mie University Graduate School of Medicine Immuno-Gene Therapy

kageyama@clin.medic.mie-u.ac.jp059-231-5187

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

MAGE-A4 peptide vaccine study after &quot;Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene&quot;